Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma

Taku Fujimura¹, Takanori Hidaka¹, Yumi Kambayashi¹, Sadanori Furudate¹, Aya Kakizaki¹, Hisayuki Tono¹, Akira Tsukada¹, Takahiro Haga¹, Akira Hashimoto¹, Ryo Morimoto², Takuhiro Yamaguchi³, Tadao Takano¹ and Setsuya Aiba¹

¹Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan
²Division of Nephrology, Endocrinology and Vascular Medicine, Department of Medicine, Tohoku University Hospital, Sendai, Japan
³Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan
⁴Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan

Correspondence to: Taku Fujimura, email: tfujimura1@mac.com

Keywords: IFN-β, PD-1, safe dose, traditional rule-based 3 + 3 design

Received: January 24, 2017  Accepted: March 21, 2017  Published: April 13, 2017

Copyright: Fujimura et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The efficacy of nivolumab is greater than that of other anti-melanoma drugs, so nivolumab-based combined therapies that enhance anti-tumor immune responses in patients with metastatic melanoma are of great interest to dermato-oncologists. As we have previously reported, IFN-β enhances the anti-tumor immune response of anti-PD-1 antibodies against B16F10 melanoma in vivo. To explore the potential of this property of IFN-β as part of a combination therapy for the treatment of metastatic melanoma patients, we performed a phase 1 trial, using a traditional rule-based 3 + 3 design, on patients with advanced melanoma. The nivolumab dose was fixed at 2 mg/kg, every 3 weeks. IFN-β was administered to three groups at doses of 1 million, 2 million, and 3 million units, respectively. Dose-limiting toxicities were defined as any grade 3-5 adverse events occurring between day 0 and day 42 that might possibly be related to nivolumab and IFN-β. Of the nine patients who received this combined therapy, none experienced dose-limiting toxicities, and all completed the treatment phase of the study. Patient follow-up continued for 6 months following the final treatment. There were two complete responses (22%) and one partial response (11%), all of which occurred in patients who had received monthly IFN-β immediately prior to the study. In this study, we determined the safe dose of IFN-β, when combined with nivolumab, to be 3 million units. To determine the efficacy of this combination therapy, further phase II trials are required.

INTRODUCTION

The PD-1/PD-L1 pathway plays a critical role in tumor immune response, so nivolumab, an IgG4 anti-PD-1 antibody, is widely used in the treatment of various cancers, including advanced melanoma [1-3]. Nivolumab significantly prolongs survival in patients with metastatic melanoma, but only 31–43% of patients who receive nivolumab monotherapy experience objective tumor regression [2, 3]. Therefore, reagents that enhance the antitumor immune response induced by nivolumab are necessary to further optimize its use for the treatment of advanced melanoma. Recently, Larkin et al. reported that ipilimumab could significantly enhance the anti-melanoma immune response in advanced melanoma patients [2]. Administration of nivolumab in combination with local therapy [4-7], such as radiotherapy or contact immunotherapy, may also lead to improved outcomes. Although recent studies suggest that such nivolumab-based combined therapy might prove effective for treatment of advanced melanoma, the associated risk of immune-related adverse events (irAE), such as severe hepatitis, interstitial pneumonia, colitis, type 1 diabetes mellitus, hypophysitis, or myasthenia gravis, is an important consideration.
Interferon beta (IFN-β) has been used clinically as an adjuvant therapy for the treatment of melanoma, especially in Japan [8-9]. We previously reported that IFN-β enhances the anti-melanoma effects of anti-PD-1 Abs in mouse B16F10 melanoma by recruiting effector cells, instead of regulatory T cells (Tregs), to tumor sites in vivo [10]. In melanoma patients, peritumoral injection of IFN-β also recruits effector cells, including CD8 and TIA1-positive cytotoxic T cells (CTLs), into the tumor microenvironment [11], which suggests a possible mechanism for the therapeutic effects of IFN-β in the treatment of melanoma. In humans, IFN-β modulates the profiles of tumor-associated macrophages (TAMs) from M2 to M1 phenotypes, leading to a decreased proportion of Tregs among tumor infiltrating leukocytes (TILs) at the tumor site [10]. The major population of TAMs is composed of CD163+ M2 polarized macrophages [12], and anti-tumor agents (e.g., IFN-α, IFN-β, or IFN-γ) could activate TAMs [10, 13], which, once activated, could increase serum soluble (s)CD163 [14] and release various autoimmune related chemokines such as CXCL5 [15, 16]. Increased serum levels of sCD163 and CXCL5 correlate not only with autoimmune diseases such as atherosclerosis and rheumatoid arthritis [15-19], but also with adverse events in melanoma patients treated with nivolumab [20].

In this study, we performed a phase I trial, using the traditional rule-based 3 + 3 design, of combined nivolumab/IFN-β to determine a safe dose of IFN-β. In addition, we evaluated the efficacy of this combination therapy for advanced melanoma. The earliest that we expected severe nivolumab-induced irAEs (e.g., colitis, skin rash) might occur was 5–6 weeks after initial administration [29], so we measured serum levels of sCD163 and CXCL5 (predictors of irAEs) at day 0 (to establish a baseline immediately before the administration of nivolumab and IFN-β) and at day 42, six weeks after the administration of nivolumab/IFN-β.

RESULTS

Patients

Nine patients were treated at Tohoku University Hospital, Sendai, Japan between January and October of 2016. All patients had received prior treatment. Patient characteristics are listed in Table 1.

Toxicities

Of the nine patients who received this combined therapy, none (0%) experienced dose-limiting toxicities (DLT), and all completed the treatment phase of the study. Patient follow-up evaluations occurred for 6 months following the final treatment. Three patients (33%) developed grade 1 or grade 2 AE (95% CI: 0%-66%). No patient in the study or follow-up phase (0%) developed grade 3 - 5 adverse events (AE). During the 6-month follow-up after the treatment period, six patients remained free of additional irAE. Two patients (cases 4 and 6) elected supportive care only during the treatment period and were lost to follow-up. One patient (case 8) developed grade 2 colitis during the treatment period, nine weeks after ipilimumab administration. Treatments were well tolerated and toxicities are summarized in Table 2.

Tumor response

There were two complete responses (irCR, 22%; 95% confidence interval [CI]: 0%-44%), one partial response (irPR, 11%; 95% CI: 0%-22%), one patient whose disease remained stable (irSD, 11%; 95% CI: 0%-22%), and five patients who experienced disease progression (irPD, 55%; 95% CI: 0%-110%). All patients who received adjuvant monthly IFN-β before the metastasis of melanoma (case 1, case 2, and case 5) responded well to nivolumab with IFN-β. The best response was in case 9, who received weekly adjuvant IFN-α and achieved stable disease. Of the other patients in this study, those who had received chemotherapy, nivolumab, or contact immunotherapy prior to melanoma metastasis progressed to disease. Hence the objective response rate was 33% (95% CI: 0%-66%). Tumor responses of individual patients are listed in Table 2. Five of the nine patients (55%) experienced disease progression and changed treatment during follow-up.

Serum levels of sCD163 and CXCL5

Compared to baseline (day 0), serum levels of sCD163 and CXCL5 at day 42 were both prominently increased in case 1, a patient who developed grade 2 isolated ACTH deficiency. The serum level of sCD163 was prominently decreased and CXCL5 was increased in case 9, a patient who developed grade 2 abdominal pain and grade 1 fever. There were no remarkable changes in sCD163 and CXCL5 levels in the remaining seven patients (Figure 1).

DISCUSSION

Because of nivolumab’s higher efficacy than other anti-melanoma drugs (e.g., ipilimumab and dacarbazine) [1, 21], and because it induces a longer duration of anti-tumor response than BRAF/MEK inhibitors (e.g., vemurafenib, dabrafenib, and trametinib) [22, 23], dermato-oncologists are particularly interested in combining nivolumab with agents that enhance the anti-tumor immune response in patients with metastatic melanoma [3, 10, 24]. The efficacy of nivolumab is significantly increased when combined with ipilimumab (57.7%), and while unfortunately the rate of severe treatment-related adverse events (grade 3 or 4) is also significantly increased with this particular combination (55.0%) [2], the findings suggest that the anti-tumor
immune response induced by nivolumab could be increased by other immune systems. Because the anti-tumor effects of nivolumab are determined, at least in part, by the number of TILs and their expression of PD-1 [3], and because IFN-β increases the number of PD-1-expressing TILs at melanoma tumor cites, in vivo [10], we hypothesized that IFN-β could improve the efficacy of nivolumab for treatment of human metastatic melanoma. Full testing of this hypothesis will require a randomized controlled phase II trial, but first, the safe dose of IFN-β to be used in the combined therapy and demonstrated that there is no increased risk of severe treatment-related AEs associated with the combination of IFN-β with nivolumab, either during the six-week treatment period or during a six-month follow-up.

CXCL5 is a biomarker of Th17-mediated autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and pemphigus vulgaris [15, 16, 25], and sCD163 is an activation marker for CD163+ TAMs that appears in the serum as a result of proteolytic shedding [17]. TAMs release CXCL5 via stimulation of periostin [26], and the tumor stroma of melanoma possesses prominent periostin [27, 28] and TAMs [8, 12], so the increased serum levels of sCD163 and CXCL5 in a patient who develops adverse nivolumab-induced, immune-related events are presumably related

### Table 1: Patient characteristics (n=9)

| Case   | Age | Sex | Stage                        | Pretreatment          | PS      | primary sites |
|--------|-----|-----|------------------------------|-----------------------|---------|---------------|
| Case 1 | 67  | M   | pT3bN3M1b stage IV          | monthly IFNβ          | ECOG 0  | sole          |
| Case 2 | 68  | M   | pT4aN3M1b stage IV          | monthly IFNβ          | ECOG 0  | sole          |
| Case 3 | 83  | F   | pT3bN2aM1a stage IV         | Nivolumab             | ECOG 1  | sole          |
| Case 4 | 93  | M   | pT4bN0M1a stage IV          | contact immunotherapy | ECOG 1  | sole          |
| Case 5 | 74  | M   | pT2bN0M1b stage IV          | monthly IFNβ          | ECOG 0  | upper arm     |
| Case 6 | 84  | F   | pT4aN3M1a stage IV          | Nivolumab             | ECOG 1  | back          |
| Case 7 | 74  | M   | pT4aN1M1b stage IV          | chemotherapy           | ECOG 0  | lower leg     |
| Case 8 | 58  | F   | pT4aN3M1c stage IV          | chemotherapy           | ECOG 0  | lower lip     |
| Case 9 | 34  | M   | pT4aN3M1c stage IV          | weekly IFN-α          | ECOG 0  | back          |

### Table 2: Patient demographic data, tumor stage, metastatic lesion status, immune-related adverse events, and tumor response.

| Case   | Pretreatment          | Metastatic lesion     | irAE               | grade | Best response |
|--------|-----------------------|-----------------------|--------------------|-------|---------------|
| Case 1 | monthly IFNβ          | lung                  | ACTH deficiencies  | 2     | irPR          |
| Case 2 | monthly IFNβ          | lung, pelvic LNs      |                    |       | irCR          |
| Case 3 | nivolumab             | pelvic LNs, in-transit|                    |       | irPD          |
| Case 4 | contact immunotherapy | pelvic LNs, in-transit|                    |       | irPD          |
| Case 5 | monthly IFNβ          | lung                  |                    |       | irCR          |
| Case 6 | nivolumab             | multiple in-transit   |                    |       | irPD          |
| Case 7 | chemotherapy           | lung, in-transit      |                    |       | irPD          |
| Case 8 | chemotherapy           | lung, liver           | fever              | 1     | irPD          |
| Case 9 | weekly IFN-α           | bile duct             | abdominal pain, fever | 2  | SD            |

PR: partial response; CR: complete response; PD: progression of disease; SD: stable disease
to periostin-stimulated TAM activation. In the setting of our combination therapy, therefore, sCD163 and CXCL5 serum levels could be valuable predictors of adverse events [20]. We therefore measured serum levels of sCD163 and CXCL5 at days 0 (immediately before the administration of nivolumab and IFN-β) and day 42, the earliest point at which severe irAEs (colitis, skin rash) caused by nivolumab might be expected to occur [29]. As mentioned above, the serum levels of sCD163 and CXCL5 were increased in case 1, a patient who developed grade 2 idiopathic ACTH deficiencies, though the increased level was not drastic compared to a previously-reported case [20] in which the patient developed grade 4 idiopathic ACTH deficiencies. The serum level of sCD163 was prominently decreased and CXCL5 was increased in case 9, a patient who developed grade 2 abdominal pain and grade 1 fever. These findings suggest that fluctuations in serum levels of sCD163 and CXCL5 might differ across the spectrum of possible adverse events. There was no remarkable change in the serum sCD163 and CXCL5 levels in patients who did not develop treatment-related adverse events.

![Figure 1: Serum levels of sCD163 and CXCL5 at days 0 and day 42. The serum levels of sCD163 (A) and CXCL5 (B) from each patient at day 0 and day 42 were examined by ELISA. These data represent changes of serum sCD163 and CXCL5 at day 42 compared to day 0.](image)

![Figure 2: The time-line of events. CBT: conventional blood test. CT: computed tomography.](image)
In this 3 + 3 design phase I clinical trial, we determined that the safe dose of IFN-β in combination with nivolumab is 3 million units. In addition, we found that the rate of complete tumor response among patients in our study was 22.2% (95% CI: 0%-44.4%), which is higher than previously reported for nivolumab monotherapy (8.9%) [2], though admittedly, the number of patients in our study was very small. It should also be noted that the patients who exhibited the best responses had received monthly adjuvant IFN-β therapy prior to melanoma metastasis, so it is possible that pre-treatment with IFN-β might also enhance the anti-tumor effects of nivolumab. Overall, our results suggest that IFN-β does not increase the rate of immune-related adverse events, and that it might enhance the anti-melanoma effects of nivolumab.

PATIENTS AND METHODS

Patients were eligible if they had unresectable stage III melanoma, if their tumor was resectable but they had declined resection, or if they had stage IV melanoma with accessible cutaneous, subcutaneous, and/or nodal lesions (patients were staged according to the AJCC Staging Manual, 7th Edition, 2011). Other inclusion criteria were: age of at least 20 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; and adequate bone marrow and liver function. Exclusion criteria were: active autoimmune disease; history of hypersensitivity to nivolumab or IFN-β; interstitial pneumonia; cancer originating in other organs; psychological disorders; and concurrent therapy with any other anti-melanoma chemotherapeutic drugs.

Study design and treatment

This phase 1 trial (UMIN000020222) was an open label, non-randomized, traditional rule-based 3 + 3 design. The intravenous administration of nivolumab was fixed at 2 mg/kg every 3 weeks (Figure 2). IFN-β was intra-dermally administered at 1 million units, 2 million units, and 3 million units to the three patients in each group at the site of the primary tumor. We set the maximum tolerated dose at the conventional IFN-β therapeutic dose approved in Japan (3 million units).

Assessment

All study patients were evaluated for DLT during the first 6 weeks of treatment. Adverse events were graded using NCI CTCAE version 4.03. DLT were defined as grade 3-5 adverse events at least possibly related to nivolumab and IFN-β that occurred between day 0 and day 42. The first three patients received nivolumab (2 mg/kg) and IFN-β (1 million units) at day 1 (dose level 1+) as per protocol design. With 0 of 3 patients exceeding a DLT of grade 3, three more patients were evaluated at dose level 2+ of nivolumab (2 mg/kg) and IFN-β (2 million units) at day 1. With no DLT reported in any of the three patients in level 2+, three more patients were evaluated at dose level 3+ of nivolumab (2 mg/kg) and IFN-β (3 million units) at day 1. With no DLT reported at level 3+, we finalized the study. After the treatment period, patients were assessed every 3 weeks with physical examination, conventional blood examination, and chest radiography, and assessed every 3 months with follow-up computed tomography (CT) scans. The tumor response was clinically evaluated by measuring the longest diameter of the target lesions over time. A partial response (irPR) was defined as a decrease of >30%, while progressive disease (irPD) was defined as an increase of >20%, as compared to the baseline measurement. Complete response (irCR) corresponded to the disappearance of all target lesions. We measured tumors 3 months and 6 months after the treatment period. Blood samples were obtained on day 0 (at the first administration of nivolumab and IFN-β), day 21 (second administration of nivolumab), and day 42 (third administration of nivolumab). We measured serum levels of sCD163 and CXCL5 at days 0 and 42.

Study oversight

The study protocol and all amendments were approved by the institutional review board at Tohoku University Graduate School of Medicine (2016-2-023). The study was conducted in accordance with the Declaration of Helsinki and with Good Clinical Practice guidelines as defined by the International Conference on Harmonisation. All patients provided written informed consent before enrollment. A data and safety monitoring committee was established to provide oversight of safety and efficacy considerations. The study was registered with UMIN (UMIN000020222).

ELISA

We analyzed day 0 and day 42 serum soluble (s) CD163 and CXCL5 levels by ELISA according to the manufacturer’s protocol (R&D Systems).

Statistical methods

For each dose group, DLT and response rate and its 95% confidence interval were estimated.

Author’s contribution

Fujimura T and Takano T designed the research study. Fujimura T, Hidaka T, Kambayashi Y, Furudate S, Tono H, Tsukada A, Haga T, Hashimoto A and Morimoto R treated the patients and acquired clinical data. Fujimura T, and Kakizaki A performed and analyzed ELISA data. Yamaguchi T contributed the statistical analysis. Fujimura T wrote the paper. Fujimura T and Aiba S supervised the study.
REFERENCES

1. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369:22–33.

2. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373:23–34.

3. Topalian SL, Szolov M, McDermott DF, Kluger HM, Carvajal RD, Sharifin WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leining PD, Lipson EJ, Puzanov I, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32:1020–30.

4. Liniker E, Menzies AM, Kong BY, Cooper A, Ramanujam S, Lo S, Kerford RF, Fargoty GB, Guminski A, Wang TW, Carlino MS, Hong A, Long GV. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncol Immunol. 2016; 5:e1214788.

5. Fujimura T, Kambayashi Y, Furudate S, Hidaka T, Sato Y, Tanita K, Tono H, Tsukada A, Hashimoto A, Aiba S. Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoints inhibitors: reports of two cases. J Dermatol. Epub ahead of print.

6. Fujimura T, Furudate S, Kakizaki A, Kambayashi Y, Haga T, Hashimoto A, Aiba S. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: two cases reports. J Dermatol. 2016; 43:686–89.

7. Gulati N, Carvajal RD, Postow MA, Wolchok JD, Krueger JG. Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer dipencyprone to immune checkpoint inhibitor treatment. Exp Dermatol. 2016; 25:553–54.

8. Aoyagi S, Hata H, Homma E, Shimizu H. Sequential local injection of low-dose interferon-beta for maintenance therapy in stage II and III melanoma: a single-institution matched case-control study. Oncology. 2012; 82:139–46.

9. Rapprich H, Hagedorn M. Intralosomal therapy of metastatic spreading melanoma with beta-interferon. J Dtsch Dermatol Ges. 2006; 4:743–46.

10. Kakizaki A, Fujimura T, Furudate S, Kambayashi Y, Yamauchi T, Yagita H, Aiba S. Immunomodulatory effect of peritumoral administered interferon-beta on melanoma through tumor-associated macrophages. Oncol Immunol. 2015; 4:e1047584–1.

11. Fujimura T, Okuyama R, Ohtani T, Ito Y, Haga T, Hashimoto A, Aiba S. Perilesional treatment of metastatic melanoma with interferon-beta. Clin Exp Dermatol. 2009; 34:793–99.

12. Fujimura T, Kakizaki A, Furudate S, Kambayashi Y, Aiba S. Tumor-associated macrophages in skin: how to treat their heterogeneity and plasticity. J Dermatol Sci. 2016; 83:167–73.

13. Furudate S, Fujimura T, Kakizaki A, Hidaka T, Asano M, Aiba S. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma. J Dermatol Sci. 2016; 83:182–89.

14. Yoshida S, Kobayashi Y, Nakama T, Zhou Y, Ishikawa K, Arita R, Nakaao S, Miyazaki M, Sassa Y, Oshima Y, Izuhara K, Kono T, Ishibashi T. Increased expression of M-CSF and IL-13 in vitrous of patients with proliferative diabetic retinopathy: implications for M2 macrophage-involving fibrovascular membrane formation. Br J Ophthalmol. 2015; 99:629–34.

15. Rumble JM, Huber AK, Krishnamoorthy G, Srinivasan A, Giles DA, Zhang X, Wang L, Segal BM. Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med. 2015; 212:23–35.

16. Fujimura T, Kakizaki A, Furudate S, Aiba S. A possible interaction between periostin and CD163(+) skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid. Exp Dermatol. Epub ahead of print.

17. Van Gorp H, Delputte PL, Nauwync HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010; 47:1650–60.

18. Aristotelis LP, Møller HJ, Bailey B, Moestrup SK, Kritharides L. The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis. 2006; 184:342–47.

19. Greisen SR, Møller HJ, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Junker P, Østergaard M, Hvid M, Deleuran B. Macrophage activity assessed by soluble CD163 marker of coronary atherosclerosis. Atherosclerosis. 2006; 184:342–47.

20. Fujimura T, Kambayashi Y, Furudate S, Kakizaki A, Hidaka T, Haga T, Hashimoto A, Morimoto R, Aiba S. Isolated ACTH deficiency possibly caused by nivolumab in a metastatic melanoma patient. J Dermatol. 2017; 44:e13–14.

21. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeel C, Kalinka-Warzocha
22. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014; 15:323–32.

23. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371:1877–88.

24. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016; 17:943–55.

25. Buckland J. Rheumatoid arthritis: citrullination alters the inflammatory properties of chemokines in inflammatory arthritis. Nat Rev Rheumatol. 2014; 10:446.

26. Furudate S, Fujimura T, Kikizaki A, Kambayashi Y, Asano M, Watabe A, Aiba S. The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides. Exp Dermatol. 2016; 25:107–12.

27. Fukuda K, Sugihara E, Ohta S, Izuhara K, Funakoshi T, Amagai M, Saya H. Periostin Is a Key Niche Component for Wound Metastasis of Melanoma. PLoS One. 2015; 10:e0129704.

28. Kotobuki Y, Yang L, Serada S, Tanemura A, Yang F, Nomura S, Kudo A, Izuhara K, Murota H, Fujimoto M, Katayama I, Naka T. Periostin accelerates human malignant melanoma progression by modifying the melanoma microenvironment. Pigment Cell Melanoma Res. 2014; 27:630–39.

29. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clin Cancer Res. 2016; 22:886–94.